Pacira Pharmaceuticals will acquire Myoscience, a targeted pain therapies company, for up to $220 million, AP News reports.
What you should know:
1. The transaction is expected to close by April.
2. Pacira's payment will include $120 million in cash up front and an additional $100 million upon achievement of commercial and regulatory milestones.
3. Under the agreement, Myoscience's iovera will become part of Pacira's portfolio.
4. Iovera freezes peripheral nerves through cryoneurolysis for opioid-free pain relief.
5. Last year, CMS approved separate payments to ASCs that use Pacira's non-opioid pain management drug, Exparel.
More articles on supply chain:
SurgCenter Development forms 200th ASC partnership — Company in 'full-growth mode'
Illinois community may benefit from ASC, OSF Regional Vice President says — 3 insights
How Southern California Orthopedic Institute shifted total joints to ASCs using bundled payments — 5 insights